Cytokinetics (CYTK) EVP exercises options and sells 15,857 shares

Rhea-AI Filing Summary

Cytokinetics EVP and Chief Commercial Officer Andrew Callos reported an exercise-and-sell transaction in company stock. On May 1, 2026, he exercised a non-qualified stock option covering 15,857 shares of common stock at $37.63 per share and sold 15,857 shares of common stock in an open-market transaction at $65.00 per share.

Following these transactions, Callos directly held 58,555 shares of Cytokinetics common stock. The exercised option had originally been scheduled to vest in equal monthly installments over four years until fully vested.

Insider Trade Summary 10b5-1

Net Seller: 15,857 shares ($1,030,705)

Net Sell 3 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 15,857 shs ($1.03M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	15,857	$0.00	--
Exercise	Common Stock	15,857	$37.63	$597K
Sale	Common Stock	15,857	$65.00	$1.03M

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 0 shares (Direct, null); Common Stock — 74,412 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 15,857 shares Sale price: $65.00 per share Option exercise size: 15,857 shares +2 more

5 metrics

Shares sold 15,857 shares Common stock sold in open-market transaction on May 1, 2026

Sale price $65.00 per share Price for 15,857 Cytokinetics common shares sold

Option exercise size 15,857 shares Non-qualified stock option exercised into common stock

Option exercise price $37.63 per share Exercise price of non-qualified stock option

Post-transaction holdings 58,555 shares Cytokinetics common stock directly held after transactions

Key Terms

Non-Qualified Stock Option, open-market sale, derivative security, vesting

4 terms

Non-Qualified Stock Option financial

"Non-Qualified Stock Option (Right to Buy)"

A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

vesting financial

"This option shall vest and become exercisable over 4 years"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/01/2026		M		15,857	A	$37.63	74,412	D
Common Stock	05/01/2026		S		15,857	D	$65	58,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$37.63	05/01/2026		M			15,857	04/01/2025(1)	03/01/2032	Common Stock	15,857	$0	0	D

Explanation of Responses:

1. This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Cytokinetics (CYTK) executive Andrew Callos report?

Andrew Callos reported exercising options and selling Cytokinetics shares. He exercised a non-qualified stock option for 15,857 common shares at $37.63 and sold 15,857 common shares in an open-market transaction at $65.00, all dated May 1, 2026.

How many Cytokinetics (CYTK) shares did Andrew Callos sell and at what price?

Andrew Callos sold 15,857 shares of Cytokinetics common stock. The sale occurred at a price of $65.00 per share in an open-market transaction on May 1, 2026, as disclosed in his Form 4 insider trading report.

What option exercise did Andrew Callos report for Cytokinetics (CYTK)?

Andrew Callos exercised a non-qualified stock option for 15,857 Cytokinetics common shares. The option had an exercise price of $37.63 per share and was fully exercised on May 1, 2026, converting the option into common stock before the reported sale.

How many Cytokinetics (CYTK) shares does Andrew Callos hold after these transactions?

After the reported transactions, Andrew Callos directly holds 58,555 shares of Cytokinetics common stock. This share count reflects his position following the exercise of 15,857 options and the same-day open-market sale of 15,857 common shares.

What is the role of Andrew Callos at Cytokinetics (CYTK) in this Form 4 filing?

In this Form 4 filing, Andrew Callos is identified as Cytokinetics’ EVP, Chief Commercial Officer. The filing details his personal transactions in Cytokinetics common stock, including an option exercise and an open-market sale completed on May 1, 2026.

How did the exercised Cytokinetics (CYTK) option held by Andrew Callos vest?

The non-qualified stock option exercised by Andrew Callos vested over four years. Shares underlying the option vested in equal monthly installments so that the option became 100% vested four years from the date of grant, according to the footnote disclosure.